New imaging agent could sharpen prostate cancer staging
NCT ID NCT06122584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial is testing whether a radioactive tracer called [18F]PSMA-1007 can improve PET/CT scans for men with newly diagnosed high-risk or very-high-risk prostate cancer. The goal is to see if it can more accurately detect cancer that has spread to pelvic lymph nodes. About 380 men will receive the tracer before undergoing prostate removal surgery, and the scan results will be compared with tissue samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]PSMA-1007 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a more accurate way to detect cancer spread in lymph nodes, helping doctors plan better treatment for high-risk prostate cancer.
What could go wrong
This is a diagnostic study, not a treatment. The tracer may not prove more accurate than current methods, and results depend on comparison with surgical tissue samples.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU de Nancy
RECRUITINGNancy, France
-
CWZ
RECRUITINGNijmegen, Netherlands
-
Carl Gustav Carus Faculty of Medicine, TUD Dresden
RECRUITINGDresden, Germany
-
Hospital Del Mar
RECRUITINGBarcelona, Spain
-
Hospital Vall d'Hebron
RECRUITINGBarcelona, Spain
-
Hospital Vithas Valencia 9 de Octubre
ACTIVE_NOT_RECRUITINGValencia, Spain
-
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
RECRUITINGMeldola, Italy
-
IRCCS Ospedale Sacro Cuore-Don Calabria
RECRUITINGVerona, Italy
-
Klinikum rechts der Isar, TUM
ACTIVE_NOT_RECRUITINGMünchen, Germany
-
National Cancer Center
RECRUITINGTokyo, Japan
-
Radboud UMC
RECRUITINGNijmegen, Netherlands
-
St. Antonius Hospital
RECRUITINGGronau, Germany
-
The University of Osaka Hospital
RECRUITINGOsaka, Japan
-
University Hospital Düsseldorf
RECRUITINGDüsseldorf, Germany
-
University Hospital Hamburg-Eppendorf
RECRUITINGHamburg, Germany
-
University Hospital Leipzig
RECRUITINGLeipzig, Germany
-
University Hospital Münster
RECRUITINGMünster, Germany
-
Universitätsmedizin Rostock
RECRUITINGRostock, Germany